Northwick Park Hospital
Harrow, Middlesex, HA1 3UJ, United Kingdom
NCT Number: NCT04488900
This study is a first-in-human, randomized, placebo-controlled, 4-part, single ascending dose and multiple ascending dose study. The study is designed to assess the safety, tolerability, PK, and PD and food effect of orally administered CKD-508 capsules and tablets in healthy subjects.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Harrow, Middlesex, HA1 3UJ, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Investigational drug
Placebo
Investigational drug
Placebo
Time frame: 28 days post the final dose
Time frame: 28 days post the final dose
Peak plasma concentration (Cmax)
Time frame: 28 days post the final dose
Time of peak plasma concentration (Tmax)
Time frame: 28 days post the final dose
Area under the plasma concentration versus time curve (AUC)
Time frame: 28 days post the final dose
Pharmacodynamics endpoint
Time frame: 14 days post the final dose
including, but not limited to the following: LDL-C, etc.
Pharmacodynamics endpoint
Chong Kun Dang Pharmaceutical
Industry
A Phase 1, First-in-Human, Double-blind, Randomized, Placebo Controlled Study to Assess the Safety, Tolerability, PK and PD and Food Effect of CKD-508 After Single and Multiple Ascending Oral Dose Administration in Healthy Adult Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07470125
Healthy Subjects
Seoul, South Korea
View Trial DetailsNCT06818032
Healthy, Healthy Adult
Burlington, Vermont, United States
View Trial DetailsNCT00761631
Healthy Subjects
Benton, Arkansas, United States
View Trial DetailsNCT02610465
Cardiac-Related Conditions, Healthy Subjects
Bethesda, Maryland, United States
View Trial Details